Exclusive enteral nutrition in Crohn’s disease: Evidence and Practicalities

James J Ashton1,2, Joan Gavin3, R Mark Beattie1

1. Department of Paediatric Gastroenterology, Southampton Children’s Hospital, Southampton
2. Human Genetics and Genomic Medicine, Faculty of Medicine, University of Southampton, Southampton
3. Department of Paediatric Dietetics, Southampton Children’s Hospital, Southampton

Correspondence to-

Professor R Mark Beattie

Department of Paediatric Gastroenterology,

Southampton Children’s Hospital,

University Hospitals Southampton

Tremona Road

Southampton

SO16 6YD

UK

Mark.beattie@uhs.nhs.uk

The authors declared no conflicts of interest

**Word count- 4503**

Search strategy

We searched the Cochrane Library, MEDLINE, Embase and relevant specialty journals for articles published between Jan 1, 1980, to September 1 2017, with the terms:

(“Crohn’s disease”, “inflammatory bowel disease” OR “IBD”) AND (“Exclusive”, “only”) AND (“Nutrition”, “Feed”, “Modulen”, “Elemental”, “Amino Acid”, “formula” OR “enteral”)

We reviewed all publications from 2007 to 2017 and prioritising those published after 2010. Commonly referenced and highly regarded older publications were also included. We searched only for articles published in English, or those translated into English. We also searched reference lists of articles identified by this strategy and selected those we judged relevant. Randomised controlled trials, observational studies, retrospective studies, meta-analyses, review articles, editorials, conference abstracts and case reports were included.

Keywords

Crohn’s disease; nutrition; paediatric; exclusive enteral nutrition

Summary

Exclusive enteral nutrition (EEN) is the first line therapy for paediatric Crohn’s disease, providing a complete nutritional feed whilst simultaneously inducing remission in up to 80% of cases. The effect of EEN on systemic/local intestinal immune function and subsequent inflammation (including barrier permeability, direct anti-inflammatory effects and cytokine signalling pathways), alongside changes in the microbiome (specific species and broad taxonomic shifts, functional changes) are becoming clearer, however the exact mechanism for induction of remission in Crohn’s disease remains uncertain. The evidence of efficacy in paediatric Crohn’s disease is strong, with selected adult populations also benefiting from EEN. However despite recommendations from all major societies (ECCO, ESPGHAN, NASPGHAN and ESPEN) first-line use of EEN is varied and Europe/Australasia/Canada show significantly more routine use than other parts of North America. Growth and nutritional status are significantly improved with EEN compared to corticosteroids but long-term outcomes are sparse. This review discusses the evidence underlying the use of EEN, highlighting the mechanisms thought to underlie how EEN induces remission in Crohn’s disease, when and how to use EEN, including practical issues in both paediatric and adult practice (formulation, compliance, volumes and administration), and summarises the ongoing research priorities.

Introduction

Exclusive enteral nutrition (EEN) is a highly effective treatment for the induction of remission in Crohn’s disease (CD). It is widely used, steroid-sparing and the first-line therapy in Paediatric CD with remission rates of 60-80% (1-3). European and Australasian use of EEN is significantly higher than in parts of North America, despite published guidance (4, 5). In adult CD there is weaker evidence of efficacy thought to relate to practicalities of use (compliance, tolerability etc.). It is recognised that many adult centres will use corticosteroids or biological agents as first line therapy (6). Despite this a proportion of adults with CD will respond well to EEN and it can be used to effectively and safely induce remission (6, 7). There is no role for EEN in the treatment of ulcerative colitis (8).

EEN was first used in the 1970s and advocated as a first line therapy from the 1990s. Contemporary consensus guidance from ECCO, ESPGHAN, ESPEN and NASPGHAN directs clinicians to use EEN to induce remission wherever possible (1, 3, 5, 9). These guidelines reinforce the position that corticosteroids, or early immunosuppressive therapy, should be reserved for those patients where EEN is not an option (1). Over the last 20 years the goals of treatment in CD have shifted from relief of symptoms to inducing mucosal healing, whilst continuing to maintain growth, nutritional status, quality of life and avoiding side effects (10). EEN remains the treatment of choice to induce deep remission (mucosal healing) in paediatric patients (1, 11). Additional benefits include avoidance of the growth retardant effects of corticosteroids and providing a complete nutritional feed correcting micro- and macro-nutrient deficiencies (3, 12). In this review the evidence underlying these assertions will be discussed through a systematic approach, highlighting the evidence behind the use of EEN in CD, how EEN works, when and how to use EEN and summarise some of the ongoing research priorities.

Mechanism of Action of EEN

Over last 5-10 years some of the precise changes in immune function (including barrier permeability, cytokine signalling pathways), microbiota (specific and broad microbiome shifts) and intestinal inflammation (direct anti-inflammatory effects) seen with EEN therapy been elucidated (13-16). See figure 1. Despite advances the exact mechanism of action has remained uncertain.

*Systemic and local immune modulation*

Systemic inflammatory markers, such as C-reactive protein and erythrocyte sedimentation rate are normalised with EEN, most often correcting before any detectable change in nutritional status (17, 18). Additionally EEN has the effect of directly reducing pro-inflammatory cytokines within the intestine, with growth failure in CD linked to increased circulating IL-6, TNF-α and TNF-ƴ (19). There is an ongoing question as to whether the improvement in growth seen with EEN is due to improved nutritional status and/or reduction in pro-inflammatory cytokines (20). In vitro modelling of intestinal inflammation has shown a direct effect on enterocytes by EEN with down-regulation of the pro-inflammatory IL-8 and IL-6 response (20, 21). There is evidence that EEN can increase the concentrations of systemic circulating anti-inflammatory cytokines, such as transforming growth factor (TGF) beta-1 (22). The active T-cell response seen in CD may directly be altered by EEN, allowing alternative production of regulatory T-cells which promote anti-inflammatory processes in the mucosa (22). Another theory relates to the direct effect of molecules such as TGF β2 (which is present in some EEN) on the intestine, however the mechanism of action remains uncertain and may involve direct downregulation of inflammatory cells or promotion of healing to the epithelial barrier (22).

In the mouse model intestinal antigen presentation through the class 2 major histocompatibility complex has been shown to be down regulated with EEN, demonstrating an impact of diet on immune and environment interaction, this may reduce the subsequent downstream inflammation induced by an environmental trigger (such as bacteria)(23, 24).

*Intestinal inflammation and barrier function*

The inflammation seen in active CD is linked to increased intestinal permeability with a breakdown of an effective barrier against bacteria and potential pro-inflammatory molecules (25). Whether this increased permeability is the cause or an effect of disease is unknown but has been demonstrated to pre-exist any active inflammation (26). Since the 1980’s it has been known that EEN has a direct anti-inflammatory effect on the intestine in CD, with improvement of the abnormal permeability after 6 weeks of EEN (27). The effect of diet on intestinal permeability and integrity of the mucus layer has been explored, some evidence suggests specific components of diet (such as wheat, emulsifiers and some fatty acids) may have adverse effects on epithelial cell tight-junctions or impair mucus function (25). A potential mechanism is that EEN allows restoration of a functional epithelial (and mucus) barrier by excluding foods that adversely affect barrier function (25).

Contemporary work has demonstrated normalisation of mucosal microRNAs over treatment with EEN, suggesting a possible role in post-transcriptional regulation of gene expression (28). In vitro modelling has shown a direct effect of polymeric formula on enterocyte differentiation and expression of molecules associated with innate response to bacteria, shaping the intestinal immune response to the microbiome (29).

Some short chain fatty acids (SCFAs), such as butyrate, have been shown to have some local anti-inflammatory properties, with changes in metabolic activity and concentration reported during treatment with EEN (30, 31). Diet can have a significant impact on relative SCFA concentrations (additional role of the microbiome) and these alterations have been demonstrated overtime with EEN, with a possible anti-inflammatory role (32, 33).

*Microbiome*

There has been an explosion of interest in the role of the microbiome in disease pathogenesis of CD over the last 5 years (34). The impact of EEN on the microbiome, including alterations of specific bacterial species, broad shifts in bacterial taxa and potential functional changes are beginning to be elucidated (14, 33, 35, 36). A recent systematic review of the effects of EEN on the microbiome concluded that despite huge variation between studies/patients, bacterial shifts, alterations in diversity and metabolomics changes over treatment were very likely to play a role in achieving remission (37).

Intestinal dysbiosis is well documented, although the exact microbial disturbances in an individual patient varies hugely (14). The advent of 16S rDNA sequencing and more recently metagenomic sequencing (shotgun sequencing) has allowed for identification of bacteria at a scale not previously possible (34). Identification of bacteria to a species level and inference of functional capability of the microbiome is realistic in both individuals and groups of patients.

The largest study to date, from the RISK inception cohort (2014), reported significant differences in mucosal bacterial abundances (in classes such as *Enterobacteriaceae, Bacteroides* and *Clostridiales)* between patients and controls but did not follow patients over time (35). Longitudinal studies have looked at the changes in microbiome diversity alongside specific bacterial species with EEN and shown a general trend towards decreased bacterial diversity during treatment (13, 31, 38, 39). Despite this several studies have demonstrated an increased abundance during the treatment phase returning to a diversity more similar to healthy controls as they enter remission (33, 40). Bacterial changes within specific taxa are reported in each study, with huge variations in the changes observed; normal gut commensal bacteria (*Bacteriodes, Prevotella, Enterobacteriaceae etc.)* have beenshown to both increase and decrease in relative abundances (38, 39, 41). The role of specific bacteria has been explored, with early studies reporting *Faecalibacterium prausnitzii* as an anti-inflammatory commensal, however more recent reports have demonstrated a reduction in abundance over treatment with EEN (42, 43). This has been replicated and the anti-inflammatory role of this bacteria has been discredited (31).

The metabolic and functional role of the microbiome in CD is of interest, with evidence suggesting disruption of normal homeostatic metabolic functions in active disease (35, 44). To date two studies have looked at the effect of EEN on the functional potential of the microbiome during treatment, both Quince et al and Ashton et al demonstrate significant functional differences in the microbiome between CD and healthy controls, returning to normal over treatment (33, 36). Interestingly Walton et al demonstrated reduction in concentrations of faecal microbial products (including potentially toxic chemicals) over treatment with EEN (45). This evidence points to a potential role of EEN in normalising intestinal microbiome function, reducing pro-inflammatory bacterial products, leading to healing.

A major limitation of current studies detailing changes in the microbiome over treatment with EEN is that they are typically conducted on faecal samples. Mucosal dysbiosis (including interaction with the host immune system) is likely to be weakly reflected in stool and therefore more subtle dysbiotic signatures and altered functional potential may not have been observed, even if it was present (35). Understanding causality regarding the microbiome and reduction in inflammation is difficult. Further work including serial mucosal sampling is required. MacLellan et al provides further appraisal of the evidence of EEN and the microbiome (14).

EEN induces remission in Paediatric Crohn’s Disease

European and North American guidelines recommend EEN as the first line agent in active luminal CD, diagnosed <17 years of age (1, 5). Early data indicated that EEN was more likely to be effective in patients with small bowel involvement; however, subsequent meta-analysis has demonstrated effectiveness regardless of site of luminal involvement (46-48). There is a paucity of data regarding the effectiveness of EEN in CD with isolated severe pancolitis, however the limited evidence appears to indicate that EEN remains an effective treatment option in selected patients (47, 49). There is limited evidence to suggest that isolated perianal CD should be treated with EEN and consensus opinion indicates that alternative therapy is used in these patients (although there may be benefit) (1, 50). No substantial evidence exists for the use of EEN in patients with extra-articular manifestations (arthritis, uveitis etc.) although there have been several reports of patients with juvenile idiopathic arthritis being effectively treated with EEN (51, 52) and successful treatment of scleritis and psoriasis in CD using only EEN (53). EEN is equally as effective as corticosteroids in induction of remission at diagnosis (47, 48, 54-57). Data focussed on induction of remission in paediatric patients with recurrent disease has shown >50% remission rates with significantly decreased disease activity in those not reaching full remission (58).

In 2007 the Cochrane review of both adult and paediatric data by Zachos et al concluded that corticosteroids were more effective than EEN at inducing remission, however acknowledgement of many confounding factors must be made (tolerability to adults, adherence to regimens, unable to double-blind studies etc.)(47). When restricting to only high quality studies the Cochrane authors found no difference between corticosteroids and EEN. Focused meta-analysis of paediatric data by Dziechciarz et al (including 4 trials and 144 patients) did not show a difference between EEN and corticosteroids (RR 0.97, 95% CI 0.68-1.40)(48). The most contemporary paediatric meta-analysis, by Swaminath et al (2017), included 8 studies and 451 patients and demonstrated no difference between corticosteroids and EEN (OR 1.26, 95% CI 0.77-2.05)(57). The summary of all meta-analyses can be seen in table 1. Cohort studies in paediatric populations have demonstrated a clinical remission rate of 60-80%, comparable to steroids (49, 59). The most contemporary data (from the last 5 years) continues to show the effectiveness of EEN. Studies from Levine et al, Grover et al (two studies) and de Bie et al demonstrated clinical remission rates of 73%, 84%, 83% and 71% respectively (17, 60-62). There are fewer recent adult data, although Yang et al, studying patients with stricturing or penetrating disease, demonstrated EEN inducing full clinical remission within 12 weeks in 80.5% of patients (63).

A further study by Grover et al (2015) retrospectively analysed 89 paediatric patients over 2 years. Data demonstrated superiority of EEN over corticosteroids as initial induction therapy when comparing 2 year corticosteroid-dependency (EEN, 7% vs CS, 43%) and primary response to anti-TNF therapy (EEN, 86% vs CS, 68%)(64). Whilst there is limited data on longer term remission rates in EEN, Berni et al followed up patients for 12 months after induction and observed lower relapse rates with EEN vs corticosteroids (65). The most contemporary data is summarised in table 2.

*Markers of inflammation*

EEN leads to rapid normalisation of markers of systemic inflammation with no significant difference between EEN and corticosteroids in meta-analysis or single centre study (57, 60). Lower faecal calprotectin levels have been associated with corticosteroid use compared to EEN, Levine et al reported only 3/23 (13%) patients treated with EEN had a faecal calprotectin <300ug/g at 8 weeks, compared to 22/72 (30.5) of those treated with corticosteroids (60).

*Nutritional status and growth*

EEN as induction therapy leads to improved nutritional status when compared to corticosteroids (15). Objective measurement has demonstrated improvement in lean mass and weight over the EEN induction period (66-69) with additional improvements in serum markers of growth such as insulin-like growth factor 1 (IGF-1)(18). Biochemical measures of nutritional status including iron and albumin levels also improve (65). Over 8 weeks of treatment with EEN Gerasimidis et al demonstrated a significant reduction in anaemia (32% to 9%) and increase in haemoglobin by 0.75 g/dL (70). Measurement of several micronutrients also demonstrated significant increases over time (66)

There is reduced incidence of linear growth failure with EEN compared to corticosteroids (7% vs 26%)(64). Berni et al demonstrated EEN increased height by over 1% over 8 weeks compared to <0.3% increase with corticosteroids, similarly Borelli et al showed an increase in height gained in those treated with EEN compared to corticosteroids (+0.8cm) (11, 65). Several historical RCTs have demonstrated superiority of EEN over corticosteroids when looking at height standard-deviation scores (SDS) with height velocity (SDS 0.32) and mean height SDS (SDS 0.3) both significantly higher with EEN (SDS -3.1 and -2.8 respectively) at 6 months (71, 72). Interestingly a meta-analysis has demonstrated that those treated with a polymeric diet gained significantly more weight (+2.5kg) than those treated with an elemental diet (48). Further studies are required with longer follow-up periods, whilst corticosteroids supress short-term growth if improved long-term remission is achieved then overall growth may be better. Future work must detail growth outcomes at >1 year to truly assess the impact of EEN/corticosteroids.

*Mucosal healing*

Mucosal healing is now seen by many as the objective treatment goal in CD (61, 73). Limited high quality data is available on the effects of EEN on mucosal healing; 2 paediatric studies (RCT and retrospective cohort) from 2006 appear to demonstrate superiority of EEN over corticosteroids at induction of mucosal healing (pooled OR 4.5, CI 95% 1.64-12.32) (11, 57, 65). Fell et al (2000) demonstrated high rates of mucosal healing with EEN, with complete remission in up to 79% of patients (74). Grover et al demonstrated improvement in endoscopy assessment with EEN in 2014, with 43% of children achieving mucosal healing and 21% achieving transmural healing (17). Grover et al (2016) showed complete mucosal healing in 33% with near complete mucosal healing in 19% of patients, complete mucosal healing was associated with sustained remission over 3 year follow-up (61).

Practical Issues

*Elemental or Polymeric Feeds*

EEN can be delivered as either a polymeric (such as Modulen, Nestle) or elemental (such as Elemental O28, Nutricia) feed. Polymeric or elemental refers to the protein source in the feed. There is no difference in efficacy between polymeric and elemental regimens for the induction of remission in either CD (odds ratio 1.10, 95% CI 0.69-1.75%)(47). Direct comparison of clinical remission rates by RCT has been performed on limited adult (polymeric 59%, elemental 80%) and paediatric patients (polymeric 82%, elemental 69% ) with no statistical differences reported (69, 75).

For several reasons (including similar efficacy data) polymeric feed regimens are more commonly used than an elemental formulations, the most recent international survey indicated >90% of centres used a polymeric feed (76, 77). Polymeric formulations are relatively palatable and lower in cost compared to elemental formulations (69, 78). There is wide variation in practice regarding the addition of flavouring to feeds and leniency regarding a small proportion of normal diet in addition to EEN (76, 77). Guidance on this is clear and recommends that feed should be exclusive with total elimination of normal diet, however addition of flavourings, sugar free sweets/chewing gum are widely used (1, 5).

Partial enteral nutrition (PEN) is not recommended for the induction of remission in CD (1); the largest study to date demonstrated paediatric patients treated with EEN reached remission in 42% compared to those treated with PEN who reached remission in only 15% (79). In a study of 90 children Lee et al demonstrated clinical remission in 64% of patients treated with PEN, compared to 88% treated with EEN and 84% treated with anti-TNF (80).

*Disease Site*

Early data suggested that EEN was more effective if there was small bowel involvement. Afzal et al (2005) supported this hypothesis; 84% patients with ileal involvement achieved remission compared to only 50% with isolated colonic disease (46). However a meta-analyses and several single centre cohort studies have failed to make the same conclusions, with similar rates of remission observed regardless of disease location (47, 49, 59, 81). This has led to the decision from ECCO/ESPGHAN/NASPGHAN to recommend EEN regardless of the site of luminal CD (1, 5). Isolated colitis/isolated small bowel disease may be different phenotypic/genotypic manifestations of disease and future work on personalised therapy may reveal groups of patients more likely to respond to EEN (82).

*Duration of Treatment*

Current recommendations are that EEN is given over a period of 6–8 weeks, either orally or by a nasogastric tube (1). Although inflammatory markers begin to fall within the first 2 weeks of EEN they continue to decrease over the 6-8 week treatment. There is considerable variation in practice, an international survey of practice by Whitten et al observed large variation in EEN duration (<6 weeks to >12 weeks) with the most common practice to continue EEN for 6-8 weeks prior to food reintroduction (57, 77). There are no controlled trials looking at the appropriate length of treatment, current practice is based on consensus opinion regarding the occurrence of clinical remission as within a 6-8 week period (1, 5).

*How much should be given?*

The correct volume of EEN considers several patient factors. The main determinant of total fluid requirement is patient body weight (see Table 1). Estimated average requirement (EAR) for energy (based on age) are used to calculate the daily calorific content of the volume of EEN required for each patient. Standard concentrations of formulae are 0.86-1kcal/ml but can be concentrated as necessary over the 6-8 week treatment period to meet satiety (and fulfil fluid/calorific requirements). Longitudinal studies have shown resting energy requirements are not increased in active CD therefore predictive energy expenditure equations are suitable for estimating requirements at all stages of disease (see Table 4) (3, 83, 84). Whilst resting energy expenditure (REE) is unchanged throughout disease there is an alteration in total energy expenditure (TEE); initially TEE decreases in comparison to healthy children due to a decrease in physical activity, during recovery there is increased physical activity with a corresponding increase in TEE with the final phase also resulting in increased TEE due to an additional energy cost of ‘catch-up’ growth once remission is achieved (83, 84). It is important to note that energy expenditure equations are only a guide (3). Daily estimated average requirement for protein follows a slightly different pattern. In active inflammation the proteolytic, catabolic response justifies an increase in protein provision to 1.2 to 1.5 g/kg body weight returning to 1g/kg body weight in remission, similar to healthy subjects (3). An additional consideration in the final few weeks of treatment with EEN is patient satiety, avoiding overfeeding is important in this stage of management (85).

Food Reintroduction

There is currently no strong evidence to guide reintroduction of food at the end of the period of EEN. As normal diet is gradually reintroduced EEN should be weaned in a proportional manner, many survey respondents adopted a method of gradually reintroducing food groups every 2-3 days over a period of 2-3 weeks whilst simultaneously decreasing EEN (1, 77). A single centre study demonstrated no difference in relapse rate between rapid food reintroduction and gradual reintroduction over 5 weeks in 39 newly diagnosed patients but this has not been replicated (86). The type of food to reintroduce remains contentious with some centres favouring a low fibre diet in the initial period (77). There are a lack of prospective, controlled, studies and insufficient evidence to recommend a specific diet. Further work is required to identify any food components that contribute to relapses or unsuccessful food reintroduction (87). The current guidance states no specific diet needs to be followed during remission (3).

*Maintenance Enteral Nutrition*

A detailed appraisal of the role of maintenance enteral nutrition (MEN) in maintaining remission is beyond the scope of this review. ESPEN guidelines suggested maintenance enteral nutrition in the form of oral nutritional supplements may be beneficial to nutritional status and anthropometry and in doing so may influence length of remission; however the evidence is not strong enough to make a recommendation (3). There is some evidence suggesting that MEN may prolong remission and be steroid-sparing (88-90) although a 2017 study by Gavin et al did not show a reduction in relapse rates at 12 months (91). Further prospective studies are required before MEN can be recommended as an effective maintenance treatment.

*Combination with other Therapy*

There is no role for EEN in combination with corticosteroids for induction of remission in CD and failure to respond to EEN within 2 weeks should trigger alternative treatment (1). Maintenance therapy (such as thiopurine/5-aminosalycylate) can be started during the period of EEN, however optimal timing of starting is controversial and is largely determined by patient’s needs and clinician preference (1, 5).

Several studies have focussed on combination of MEN with other maintenance medication, reporting improved remission rates in children treated with MEN alongside normal diet and maintenance medications (92, 93). Adult data from a systematic review of 10 studies concluded that there was benefit from MEN alongside maintenance medications in prolonging remission in CD and two additional studies focused on anti-TNF therapy have demonstrated benefit (89, 90, 94). Nguyen et al demonstrated 45% of patients remaining in remission on anti-TNF monotherapy compared to 75% on both anti-TNF therapy and EEN at 1 year (95). Yamamoto et al failed to demonstrate any improvement in patients remaining in remission between those on MEN (76%) and those on normal diet (67%), P=0.51 (96).

Use of EEN in Adult Disease

The basic premise of EEN as an effective treatment in adult CD remains the same as in paediatric practice; however the evidence of efficacy in adults is significantly less than in children. This is likely to be related to practical issues (disruption to normal life, poor palatability, less multi-disciplinary team support, lack of experience, lack of guidance) rather than mechanistic differences (how EEN works)(97). Consensus clinical guidelines in Europe and North America do not recommend EEN as first line therapy to induce remission (98, 99). In contrast Japanese clinicians recommend EEN for routine use (100). A recent review on adult disease found evidence from 7 studies demonstrating no difference between EEN and corticosteroids in inducing remission (remission rates varied hugely from 20-100%) (101). The same review identified the main barrier to successful treatment with EEN was adherence, with up to 41% of patients dropping out of EEN treatment, rates much higher than with steroid therapy (101). Overcoming obstacles to treatment (such as with use of NGT) and focussing on specific patient groups who may benefit from therapy (newly diagnosed, possibly small bowel involvement) may allow the nutritional benefits and similar efficacy to paediatric disease (101).

Essential role of the Dietitian and Multi-Disciplinary Team

A dietitian with an interest in IBD should undertake a full nutritional assessment at diagnosis prior to commencing EEN (figure 2) (3). This assessment should include:

* Anthropometric measures e.g. weight, height, BMI and body composition measures (skinfold thickness or mid upper arm circumference).
* Assessment of refeeding risk; for patients who have eaten little over the past 5 days, had unintentional weight loss >10% over the last 3-6 months or who are malnourished (BMISDS< -1) should have no more than 50% of energy requirements as EEN initially. There should be a plan to increase to full requirements within 4-7 days if refeeding changes are not detected on clinical and biochemical monitoring (102).
* Calculation of protein and energy requirements throughout the EEN period, with consideration to the change in requirements during recovery.

Advice on the practical aspects of incorporating EEN into daily life including how to reconstitute the feed correctly should all be discussed at diagnosis. Regular contact between the dietitian and patient should take place throughout the EEN feeding period to aid compliance and to ensure satiety. A full nutritional assessment should be undertaken again at the end of the EEN period to assess the need for ongoing nutritional support (103).

Monitoring of compliance to treatment is important and patients failing to tolerate full volumes should be considered for an alternative route of administration (1). There is a role for nasogastric tubes (NGT) in selected patients. Importantly there are no reported differences in efficacy of induction of remission when comparing fractionated oral feeds to continuous feeds (59). Where patients are unable to tolerate due to palatability a NGT may be considered. Comparison of compliance of oral to NGT administration is variable, older data from Griffiths et al in 1995 that demonstrated compliance improved to 87-100% when feeds were administered by nasogastric tube (104). More contemporary data has shown that between 56-93% of patients will tolerate EEN orally for the duration of their treatment, with the impact of multi-disciplinary support being key in increasing compliance (77, 85).

Identification of patients and physician barriers to effective treatment with EEN (including tolerance/compliance and psychological problems), with subsequent MDT support (dietetic, specialist nursing and psychological support) is important in improving EEN compliance (105). Quality of life data in patients treated with EEN do show improvement in line with decreasing disease activity scores, often equal or better than with corticosteroid therapy, however disruption of normal diet and additional difficulties with daily routines must be addressed (107).

Future research priorities

The efficacy of EEN in induction of remission in paediatric CD is clear, however questions remain as to the exact mechanism through which EEN acts and additionally which patients are likely to respond best. Stratification of patients to guide treatment, through merging of clinical and multi-omic data by machine learning is a clear research priority. Understanding the exact mechanisms including prospective and longitudinal assessment of changes in the microbiome and alterations immune response may lead to improved application of EEN in both children and adults. Additionally preventing relapse through maintenance enteral nutrition and the potential of an alternative to EEN through an exclusion diet presents further interesting avenues for research.

Conclusions

EEN is an effective, low risk and steroid-sparing treatment for induction of remission in paediatric CD, with some evidence-suggesting efficacy in adult disease, where EEN is underused. Modulation of intestinal microbiota, direct gut anti-inflammatory effects and systemic immune changes act to induce remission in newly-diagnosed and relapsed CD.

**Declaration of interest**

The authors have no conflicts of interest to declare.

**Sources of funding**

JJA is funded by an ACTION MEDICAL RESEARCH, Research Training Fellowship. JG is funded by Health Education England Wessex. There was no specific funding for writing this article.

**Contributorship**

RMB and JJA conceived the article. JJA conducted the searches for articles in conjunction with JG and RMB. JJA wrote the article in conjunction with JG and RMB. JG had specific input on dietetic sections. All authors approved the manuscript prior to final submission

Figures

**Figure 1**- Summary of mechanisms of action through which exclusive enteral nutrition induces remission in Crohn’s disease. Restoration of epithelial barrier function with no invasion of bacteria into the mucosa, reduction in inflammatory response (mediated through reduction of pro-inflammatory cytokines and local action of anti-inflammatory cytokines and normalisation of handling of bacteria, with alterations in the composition of the microbiome.

**Figure 2**- Treatment algorithm for use of exclusive enteral nutrition as induction therapy in paediatric Crohn’s disease

Tables

**Table 1-** Summary of four meta-analyses comparing exclusive enteral nutrition to corticosteroids for induction of remission in Crohn’s disease

**Table 2**- Summary of studies on exclusive enteral nutrition from last 5 years detailing remission rates, duration of treatment, patient numbers and type of feed

**Table 3**- Nutritional comparison of a polymeric (Modulen, Nestle) and elemental (EO28 Nutricia) exclusive enteral nutrition feed

**Table 4**- Estimated Average Requirement for energy, fluid requirements and TEE in male and female children aged 10-18

References

1. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014;8(10):1179-207.

2. Sandhu BK, Fell JM, Beattie RM, Mitton SG, Wilson DC, Jenkins H, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr. 2010;50 Suppl 1:S1-13.

3. Forbes A, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider S, et al. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin Nutr. 2017;36(2):321-47.

4. Levine A, Milo T, Buller H, Markowitz J. Consensus and controversy in the management of pediatric Crohn disease: an international survey. J Pediatr Gastroenterol Nutr. 2003;36(4):464-9.

5. Critch J, Day AS, Otley A, King-Moore C, Teitelbaum JE, Shashidhar H, et al. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2012;54(2):298-305.

6. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571-607.

7. Li G, Ren J, Wang G, Hu D, Gu G, Liu S, et al. Preoperative exclusive enteral nutrition reduces the postoperative septic complications of fistulizing Crohn's disease. Eur J Clin Nutr. 2014;68(4):441-6.

8. Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55(3):340-61.

9. Voitk AJ, Echave V, Feller JH, Brown RA, Gurd FN. Experience with elemental diet in the treatment of inflammatory bowel disease. Is this primary therapy? Arch Surg. 1973;107(2):329-33.

10. Aloi M, Nuti F, Stronati L, Cucchiara S. Advances in the medical management of paediatric IBD. Nat Rev Gastroenterol Hepatol. 2014;11(2):99-108.

11. Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4(6):744-53.

12. Sanderson IR. Growth problems in children with IBD. Nat Rev Gastroenterol Hepatol. 2014;11(10):601-10.

13. Kaakoush NO, Day AS, Leach ST, Lemberg DA, Mitchell HM. Reduction in Gut Microbial Diversity as a Mechanism of Action of Exclusive Enteral Nutrition. Am J Gastroenterol. 2016;111(7):1033.

14. MacLellan A, Moore-Connors J, Grant S, Cahill L, Langille MGI, Van Limbergen J. The Impact of Exclusive Enteral Nutrition (EEN) on the Gut Microbiome in Crohn's Disease: A Review. Nutrients. 2017;9(5).

15. Day AS, Lopez RN. Exclusive enteral nutrition in children with Crohn's disease. World J Gastroenterol. 2015;21(22):6809-16.

16. Day AS, Burgess L. Exclusive enteral nutrition and induction of remission of active Crohn's disease in children. Expert Rev Clin Immunol. 2013;9(4):375-83; quiz 84.

17. Grover Z, Muir R, Lewindon P. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease. J Gastroenterol. 2014;49(4):638-45.

18. Bannerjee K, Camacho-Hübner C, Babinska K, Dryhurst KM, Edwards R, Savage MO, et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr. 2004;38(3):270-5.

19. Heuschkel RB, MacDonald TT, Monteleone G, Bajaj-Elliott M, Smith JA, Pender SL. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease. Gut. 2000;47(1):57-62.

20. Sanderson IR, Croft NM. The anti-inflammatory effects of enteral nutrition. JPEN J Parenter Enteral Nutr. 2005;29(4 Suppl):S134-8; discussion S8-40, S84-8.

21. de Jong NS, Leach ST, Day AS. Polymeric formula has direct anti-inflammatory effects on enterocytes in an in vitro model of intestinal inflammation. Dig Dis Sci. 2007;52(9):2029-36.

22. MacDonald TT, Di Sabatino A, Gordon JN. Immunopathogenesis of Crohn's disease, J Parenter Enteral Nutr. 2005;29(4 Suppl):S118-24

23. Sanderson IR, Ouellette AJ, Carter EA, Harmatz PR. Ontogeny of Ia messenger RNA in the mouse small intestinal epithelium is modulated by age of weaning and diet. Gastroenterology. 1993;105(4):974-80.

24. Sanderson IR, Bustin SA, Dziennis S, Paraszczuk J, Stamm DS. Age and diet act through distinct isoforms of the class II transactivator gene in mouse intestinal epithelium. Gastroenterology. 2004;127(1):203-12.

25. Levine A, Wine E. Effects of enteral nutrition on Crohn's disease: clues to the impact of diet on disease pathogenesis. Inflamm Bowel Dis. 2013;19(6):1322-9.

26. Vetrano S, Rescigno M, Cera MR, Correale C, Rumio C, Doni A, et al. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology. 2008;135(1):173-84.

27. Sanderson IR, Boulton P, Menzies I, Walker-Smith JA. Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet. Gut. 1987;28(9):1073-6.

28. Guo Z, Gong J, Li Y, Gu L, Cao L, Wang Z, et al. Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn's Disease. Nutrients. 2016;8(8).

29. Budd GR, Aitchison A, Day AS, Keenan JI. The effect of polymeric formula on enterocyte differentiation. Innate Immun. 2017;23(3):240-8.

30. Sanderson IR. Short chain fatty acid regulation of signaling genes expressed by the intestinal epithelium. J Nutr. 2004;134(9):2450S-4S.

31. Gerasimidis K, Bertz M, Hanske L, Junick J, Biskou O, Aguilera M, et al. Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn's disease during enteral nutrition. Inflamm Bowel Dis. 2014;20(5):861-71.

32. Sanderson IR. Nutritional factors and immune functions of gut epithelium. Proc Nutr Soc. 2001;60(4):443-7.

33. Ashton JJ, Colquhoun CM, Cleary DW, Coelho T, Haggarty R, Mulder I, et al. 16S sequencing and functional analysis of the fecal microbiome during treatment of newly diagnosed pediatric inflammatory bowel disease. Medicine (Baltimore). 2017;96(26):e7347.

34. Ashton JJ, Beattie RM, Ennis S, Cleary DW. Analysis and Interpretation of the Human Microbiome. Inflamm Bowel Dis. 2016;22(7):1713-22.

35. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014;15(3):382-92.

36. Quince C, Ijaz UZ, Loman N, Eren AM, Saulnier D, Russell J, et al. Extensive Modulation of the Fecal Metagenome in Children With Crohn's Disease During Exclusive Enteral Nutrition. Am J Gastroenterol. 2015.

37. Gatti S, Galeazzi T, Franceschini E, Annibali R, Albano V, Verma AK, et al. Effects of the Exclusive Enteral Nutrition on the Microbiota Profile of Patients with Crohn's Disease: A Systematic Review. Nutrients. 2017;9(8).

38. Kaakoush NO, Day AS, Leach ST, Lemberg DA, Nielsen S, Mitchell HM. Effect of exclusive enteral nutrition on the microbiota of children with newly diagnosed Crohn's disease. Clin Transl Gastroenterol. 2015;6:e71.

39. Leach ST, Mitchell HM, Eng WR, Zhang L, Day AS. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn's disease. Aliment Pharmacol Ther. 2008;28(6):724-33.

40. D'Argenio V, Precone V, Casaburi G, Miele E, Martinelli M, Staiano A, et al. An altered gut microbiome profile in a child affected by Crohn's disease normalized after nutritional therapy. Am J Gastroenterol. 2013;108(5):851-2.

41. Dunn KA, Moore-Connors J, MacIntyre B, Stadnyk AW, Thomas NA, Noble A, et al. Early Changes in Microbial Community Structure Are Associated with Sustained Remission After Nutritional Treatment of Pediatric Crohn's Disease. Inflamm Bowel Dis. 2016;22(12):2853-62.

42. Jia W, Whitehead RN, Griffiths L, Dawson C, Waring RH, Ramsden DB, et al. Is the abundance of Faecalibacterium prausnitzii relevant to Crohn's disease? FEMS Microbiol Lett. 2010;310(2):138-44.

43. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731-6.

44. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13(9):R79.

45. Walton C, Montoya MP, Fowler DP, Turner C, Jia W, Whitehead RN, et al. Enteral feeding reduces metabolic activity of the intestinal microbiome in Crohn's disease: an observational study. Eur J Clin Nutr. 2016;70(9):1052-6.

46. Afzal NA, Davies S, Paintin M, Arnaud-Battandier F, Walker-Smith JA, Murch S, et al. Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig Dis Sci. 2005;50(8):1471-5.

47. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2007(1):CD000542.

48. Dziechciarz P, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition in active Crohn's disease in children. Aliment Pharmacol Ther. 2007;26(6):795-806.

49. Buchanan E, Gaunt WW, Cardigan T, Garrick V, McGrogan P, Russell RK. The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009;30(5):501-7.

50. Wong S, Lemberg DA, Day AS. Exclusive enteral nutrition in the management of perianal Crohn's disease in children. J Dig Dis. 2010;11(3):185-8.

51. Berntson L, Hedlund-Treutiger I, Alving K. Anti-inflammatory effect of exclusive enteral nutrition in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2016;34(5):941-5.

52. Berntson L. Anti-inflammatory effect by exclusive enteral nutrition (EEN) in a patient with juvenile idiopathic arthritis (JIA): brief report. Clin Rheumatol. 2014;33(8):1173-5.

53. Triantafillidis JK, Mantzaris G, Stamataki A, Asvestis K, Malgarinos G, Gikas A. Complete remission of severe scleritis and psoriasis in a patient with active Crohn's disease using Modulen IBD as an exclusive immunomodulating diet. J Clin Gastroenterol. 2008;42(5):550-1.

54. Tjellstrom B, Hogberg L, Stenhammar L, Magnusson KE, Midtvedt T, Norin E, et al. Effect of exclusive enteral nutrition on gut microflora function in children with Crohn's disease. Scandinavian Journal of Gastroenterology.47(12):1454-9.

55. Heuschkel R. Enteral nutrition should be used to induce remission in childhood Crohn's disease. Dig Dis. 2009;27(3):297-305.

56. Grogan JL, Casson DH, Terry A, Burdge GC, El-Matary W, Dalzell AM. Enteral feeding therapy for newly diagnosed pediatric Crohn's disease: a double-blind randomized controlled trial with two years follow-up. Inflamm Bowel Dis. 2012;18(2):246-53.

57. Swaminath A, Feathers A, Ananthakrishnan AN, Falzon L, Li Ferry S. Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. Aliment Pharmacol Ther. 2017.

58. Day AS, Whitten KE, Lemberg DA, Clarkson C, Vitug-Sales M, Jackson R, et al. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol. 2006;21(10):1609-14.

59. Rubio A, Pigneur B, Garnier-Lengliné H, Talbotec C, Schmitz J, Canioni D, et al. The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral feeding. Aliment Pharmacol Ther. 2011;33(12):1332-9.

60. Levine A, Turner D, Pfeffer Gik T, Amil Dias J, Veres G, Shaoul R, et al. Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study. Inflamm Bowel Dis. 2014;20(2):278-85.

61. Grover Z, Burgess C, Muir R, Reilly C, Lewindon PJ. Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn's disease. J Crohns Colitis. 2016;10(10):1159-64.

62. de Bie C, Kindermann A, Escher J. Use of exclusive enteral nutrition in paediatric Crohn's disease in The Netherlands. J Crohns Colitis. 2013;7(4):263-70.

63. Yang Q, Gao X, Chen H, Li M, Wu X, Zhi M, et al. Efficacy of exclusive enteral nutrition in complicated Crohn's disease. Scand J Gastroenterol. 2017;52(9):995-1001.

64. Grover Z, Lewindon P. Two-Year Outcomes After Exclusive Enteral Nutrition Induction Are Superior to Corticosteroids in Pediatric Crohn's Disease Treated Early with Thiopurines. Dig Dis Sci. 2015;60(10):3069-74.

65. Canani Berni R, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis. 2006;38(6):381-7.

66. Gerasimidis K, Talwar D, Duncan A, Moyes P, Buchanan E, Hassan K, et al. Impact of exclusive enteral nutrition on body composition and circulating micronutrients in plasma and erythrocytes of children with active Crohn's disease. Inflamm Bowel Dis. 2012;18(9):1672-81.

67. Khoshoo V, Reifen R, Neuman MG, Griffiths A, Pencharz PB. Effect of low- and high-fat, peptide-based diets on body composition and disease activity in adolescents with active Crohn's disease. JPEN J Parenter Enteral Nutr. 1996;20(6):401-5.

68. Azcue M, Rashid M, Griffiths A, Pencharz PB. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. Gut. 1997;41(2):203-8.

69. Ludvigsson JF, Krantz M, Bodin L, Stenhammar L, Lindquist B. Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. Acta Paediatr. 2004;93(3):327-35.

70. Gerasimidis K, Barclay A, Papangelou A, Missiou D, Buchanan E, Tracey C, et al. The epidemiology of anemia in pediatric inflammatory bowel disease: prevalence and associated factors at diagnosis and follow-up and the impact of exclusive enteral nutrition. Inflamm Bowel Dis. 2013;19(11):2411-22.

71. Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. J Pediatr Gastroenterol Nutr. 1993;17(1):75-81.

72. Sanderson IR, Udeen S, Davies PS, Savage MO, Walker-Smith JA. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child. 1987;62(2):123-7.

73. Darr U, Khan N. Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature. Curr Treat Options Gastroenterol. 2017.

74. Fell JM, Paintin M, Arnaud-Battandier F, Beattie RM, Hollis A, Kitching P, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther. 2000;14(3):281-9.

75. Verma S, Brown S, Kirkwood B, Giaffer MH. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. Am J Gastroenterol. 2000;95(3):735-9.

76. Gråfors JM, Casswall TH. Exclusive enteral nutrition in the treatment of children with Crohn's disease in Sweden: a questionnaire survey. Acta Paediatr. 2011;100(7):1018-22.

77. Whitten KE, Rogers P, Ooi CY, Day AS. International survey of enteral nutrition protocols used in children with Crohn's disease. J Dig Dis. 2012;13(2):107-12.

78. Rodrigues AF, Johnson T, Davies P, Murphy MS. Does polymeric formula improve adherence to liquid diet therapy in children with active Crohn's disease? Arch Dis Child. 2007;92(9):767-70.

79. Johnson T, Macdonald S, Hill SM, Thomas A, Murphy MS. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut. 2006;55(3):356-61.

80. Lee D, Baldassano RN, Otley AR, Albenberg L, Griffiths AM, Compher C, et al. Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohn's Disease. Inflamm Bowel Dis. 2015;21(8):1786-93.

81. Knight C, El-Matary W, Spray C, Sandhu BK. Long-term outcome of nutritional therapy in paediatric Crohn's disease. Clin Nutr. 2005;24(5):775-9.

82. Mossotto E, Ashton JJ, Coelho T, Beattie RM, MacArthur BD, Ennis S. Classification of Paediatric Inflammatory Bowel Disease using Machine Learning. Sci Rep. 2017;7(1):2427.

83. Wiskin AE, Wootton SA, Cornelius VR, Afzal NA, Elia M, Beattie RM. No relation between disease activity measured by multiple methods and REE in childhood Crohn disease. J Pediatr Gastroenterol Nutr. 2012;54(2):271-6.

84. Wiskin AE, Beattie RM. Energy requirements in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2008;47(5):672; autor reply -3.

85. Gavin J, Anderson CE, Bremner AR, Beattie RM. Energy intakes of children with Crohn's disease treated with enteral nutrition as primary therapy. J Hum Nutr Diet. 2005;18(5):337-42.

86. Faiman A, Mutalib M, Moylan A, Morgan N, Crespi D, Furman M, et al. Standard versus rapid food reintroduction after exclusive enteral nutritional therapy in paediatric Crohn's disease. Eur J Gastroenterol Hepatol. 2014;26(3):276-81.

87. Durchschein F, Petritsch W, Hammer HF. Diet therapy for inflammatory bowel diseases: The established and the new. World J Gastroenterol. 2016;22(7):2179-94.

88. Esaki M, Matsumoto T, Hizawa K, Nakamura S, Jo Y, Mibu R, et al. Preventive effect of nutritional therapy against postoperative recurrence of Crohn disease, with reference to findings determined by intra-operative enteroscopy. Scand J Gastroenterol. 2005;40(12):1431-7.

89. Tanaka T, Takahama K, Kimura T, Mizuno T, Nagasaka M, Iwata K, et al. Effect of concurrent elemental diet on infliximab treatment for Crohn's disease. J Gastroenterol Hepatol. 2006;21(7):1143-9.

90. Yamamoto T, Shiraki M. Efficacy of enteral nutrition during infliximab maintenance therapy in patients with Crohn's disease. Dig Dis Sci. 2013;58(6):1802-3.

91. Gavin J, Ashton JJ, Heather N, Marino LV, Beattie RM. Nutritional support in paediatric Crohn's disease; Outcome at 12 months. Acta Paediatr. 2017.

92. Wilschanski M, Sherman P, Pencharz P, Davis L, Corey M, Griffiths A. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut. 1996;38(4):543-8.

93. Belli DC, Seidman E, Bouthillier L, Weber AM, Roy CC, Pletincx M, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology. 1988;94(3):603-10.

94. Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K. Enteral nutrition for the maintenance of remission in Crohn's disease: a systematic review. Eur J Gastroenterol Hepatol. 2010;22(1):1-8.

95. Nguyen DL, Palmer LB, Nguyen ET, McClave SA, Martindale RG, Bechtold ML. Specialized enteral nutrition therapy in Crohn's disease patients on maintenance infliximab therapy: a meta-analysis. Therap Adv Gastroenterol. 2015;8(4):168-75.

96. Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K. Prospective clinical trial: enteral nutrition during maintenance infliximab in Crohn's disease. J Gastroenterol. 2010;45(1):24-9.

97. Smith MA, Smith T, Trebble TM. Nutritional management of adults with inflammatory bowel disease: practical lessons from the available evidence. Frontline Gastroenterol. 2012;3(3):172-9.

98. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis. 2010;4(1):28-62.

99. Lichtenstein GR, Hanauer SB, Sandborn WJ, Gastroenterology PPCoACo. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104(2):465-83; quiz 4, 84.

100. Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M, et al. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: A randomized-controlled trial. Aliment Pharmacol Ther. 2006;24(9):1333-40.

101. Wall CL, Day AS, Gearry RB. Use of exclusive enteral nutrition in adults with Crohn's disease: a review. World J Gastroenterol. 2013;19(43):7652-60.

102. Afzal NA, Addai S, Fagbemi A, Murch S, Thomson M, Heuschkel R. Refeeding syndrome with enteral nutrition in children: a case report, literature review and clinical guidelines. Clin Nutr. 2002;21(6):515-20.

103. Kammermeier J, Morris MA, Garrick V, Furman M, Rodrigues A, Russell RK, et al. Management of Crohn's disease. Arch Dis Child. 2016;101(5):475-80.

104. Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology. 1995;108(4):1056-67.

105. Stewart M, Day AS, Otley A. Physician attitudes and practices of enteral nutrition as primary treatment of paediatric Crohn disease in North America. J Pediatr Gastroenterol Nutr. 2011;52(1):38-42.

106. Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, Davies S, Murch S, Derkx B, et al. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther. 2004;20(2):167-72.

107. Gailhoustet L, Goulet O, Cachin N, Schmitz J. [Study of psychological repercussions of 2 modes of treatment of adolescents with Crohn's disease]. Arch Pediatr. 2002;9(2):110-6.

108. Lambert B, Lemberg DA, Leach ST, Day AS. Longer-term outcomes of nutritional management of Crohn's disease in children. Dig Dis Sci. 2012;57(8):2171-7.

109. Saadah OI. Childhood onset of Crohn disease: experience from a university teaching hospital in Saudi Arabia. Ann Saudi Med. 2012;32(6):596-602.

110. Soo J, Malik BA, Turner JM, Persad R, Wine E, Siminoski K, et al. Use of exclusive enteral nutrition is just as effective as corticosteroids in newly diagnosed pediatric Crohn's disease. Dig Dis Sci. 2013;58(12):3584-91.

111. Hojsak I, Pavić AM, Mišak Z, Kolaček S. Risk factors for relapse and surgery rate in children with Crohn's disease. Eur J Pediatr. 2014;173(5):617-21.

112. Luo Y, Yu J, Zhao H, Lou J, Chen F, Peng K, et al. Short-Term Efficacy of Exclusive Enteral Nutrition in Pediatric Crohn's Disease: Practice in China. Gastroenterol Res Pract. 2015;2015:428354.

113. Connors J, Basseri S, Grant A, Giffin N, Mahdi G, Noble A, et al. Exclusive Enteral Nutrition Therapy in Paediatric Crohn's Disease Results in Long-term Avoidance of Corticosteroids: Results of a Propensity-score Matched Cohort Analysis. J Crohns Colitis. 2017;11(9):1063-70.

114. Scientific Advisory Committee on Nutrition (SACN), Dietary Reference Values for Energy, 1/11/2011, published on behalf of Public Health England.